Eye drops for early diabetic eye disease
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests if a new eye drop, NPDR-01, can help slow or improve early diabetic retinopathy (damage to the retina caused by diabetes). It is for people with type 1 or type 2 diabetes who have non-proliferative diabetic retinopathy and have not had certain eye treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 35 and 75 years old
- You have type 1 or type 2 diabetes with non-proliferative diabetic retinopathy (early stage, with small blood vessel changes in the eye)
- Your diabetes has been diagnosed for at least 1 year and your HbA1c (average blood sugar over 3 months) is 10% or lower
- You have not had laser treatment or injections in your eye for retinopathy, and don't need them in the next 6 months
- You have no other serious eye diseases like macular edema (swelling in the central part of the retina) or advanced retinopathy
- You are not pregnant, breastfeeding, or using blood thinners like aspirin or warfarin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye drop (QLS-111) to see if it improves blood flow in the back of the eye. It may help people with mild to moderate glaucoma or stable diabetic retinopathy by reducing pressure inside the eye and nourishing the optic nerve.
This trial tests whether an extract from the ginkgo tree can help prevent or slow vision loss in people with diabetes who have early signs of diabetic retinopathy. It is for patients who have not yet received eye treatments like laser or injections.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This early-phase study tests a treatment aimed at preventing or slowing early diabetic eye disease in people with mild, early changes. You may be considered if your diabetes is moderately controlled and your eye tests show early warning signs.
This trial tests if an oral medication called VX-01 can help people with diabetic eye disease (non-proliferative diabetic retinopathy) that is moderate to severe but not yet at the most advanced stage. It may be an option if you have type 1 or type 2 diabetes and have not had certain prior eye treatments.
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.